scholarly journals Efficacy of trimebutine in the treatment of functional gastrointestinal disorders: an observational multicenter study

2021 ◽  
Vol 93 (8) ◽  
pp. 897-903
Author(s):  
Dmitry N. Andreev ◽  
Igor V. Maev
Keyword(s):  
Abdominal Pain ◽  
Rating Scale ◽  
Epigastric Pain ◽  
Functional Gastrointestinal Disorders ◽  
Sphincter Of Oddi ◽  
Gastrointestinal Disorders ◽  
Sphincter Of Oddi Dysfunction ◽  
Interventional Study ◽  
Biliary Pain ◽  
Postprandial Fullness

Aim. Evaluation of the practice of using trimebutine (tablets, 300 mg, extended release), for the treatment of patients with functional gastrointestinal disorders (FGID) in primary health care. Materials and methods. A prospective observational multicenter non-interventional study was carried out, which included patients of both sexes aged 18 to 60 years with a verified diagnosis of functional gastrointestinal disorders (functional dyspepsia, irritable bowel syndrome, biliary tract dysfunction, sphincter of Oddi dysfunction, postcholecystectomy syndrome). Trimebutine was prescribed in accordance with the instructions for medical use: orally, 300 mg twice per day for 28 days. The severity of simptoms was evaluated by five-point rating scale. Results. The study included 4433 patients, the per protocol sample consisted of 3831 people. The proportion of patients with a significant decrease in the severity of abdominal pain after treatment was 74.73% (95% confidence interval CI 73.3276.11). At the and of the study a statistically significant decrease in the severity of FGID` simptoms was observed: epigastric pain/burning (mean score at the 1st visit was 1.21 [95% CI 1.181.25], at the 2nd visit 0.22 [95% CI 0.20.23]; p0.001), abdominal pain (1st visit 2.01 [95% CI 1.982.04), 2nd visit 0.33 [95% CI 0.310.35]; p0.001), biliary pain (1st visit 1.22 [95% CI 1.181.26], 2nd visit 0.2 [95% CI 0.190.22]; p0.001), postprandial fullness and early satiation (1st visit 1.29 [95% CI 1.251.32], 2nd visit 0.21 [95% CI 0.190.22]; p0.001), severity of heartburn (1st visit 0.92 [95% CI 0.880.95], 2nd visit 0.18 [95% CI 0.170.20]; p0.001), belching (1st visit 1.13 [95% CI 1.091.16], 2nd visit 0.22 [95% CI 0.210.24]; p0.001), as well as abdominal distention (1st visit 1.99 (95% CI 1, 96, 2.03), 2nd visit 0.43 [95% CI 0.410.45]; p0.001). Conclusion. The present prospective observational multicenter non-interventional study has demonstrated that trimebutine is an effective approach to treating FGID.

scholarly journals Disorders of the gallbladder and sphincter of Oddi in the Rome criteria IV: diagnostic capabilities, or searching for a “gold standard”

2017 ◽  
Vol 38 (4) ◽  
pp. 53-63
Author(s):  
L. V. Zhuravlyova ◽  
T. A. Moiseyenko ◽  
M. V. Filonenko ◽  
A. K. Zhuravlyova
Keyword(s):  
Gold Standard ◽  
Functional Gastrointestinal Disorders ◽  
Historical Context ◽  
Sphincter Of Oddi ◽  
Gastrointestinal Disorders ◽  
Rome Criteria ◽  
Biliary Pain ◽  
Significant Interest ◽  
Diagnostic Capabilities ◽  
Methods Of Treatment

The aim of the work is to study and describe modern ideas on the functional gallbladder and sphincter of Oddi disorders (FGSOD). The main methods of FGSOD diagnosis are described, their diagnostic capabilities and possible adverse consequences are indicated. The changes of indications for the use of invasive methods of FGSOD diagnosis and treatment are reflected through the historical context. A comparative analysis of FGSOD classifications in the Rome criteria for functional gastrointestinal disorders in 2006 and 2016 was conducted. The main results of the most significant studies, devoted to the different variants of FGSOD, carried out in various countries during the last decade, are given. The new pathogenetic concepts about the mechanism of biliary pain and the methods of treatment of FGSOD are described. The refined diagnostic criteria of FGSOD can be of significant interest to practicing gastroenterologists and therapists.

scholarly journals Efficacy of Hymecromone in Post-Cholecystectomy Patients

2021 ◽  
Vol 31 (4) ◽  
pp. 37-44
Author(s):  
A V. Okhlobystin ◽  
A. К. Ufimtseva ◽  
M. A. Tatarkina ◽  
O. Z. Okhlobystina ◽  
V. T. Ivashkin
Keyword(s):  
Abdominal Pain ◽  
Gallstone Disease ◽  
Sphincter Of Oddi ◽  
Sphincter Of Oddi Dysfunction ◽  
Biliary Pain ◽  
Full Dose ◽  
Half Dose ◽  
Group A ◽  
Group B ◽  
Symptomatic Gallstone Disease

Background. The cholecystectomy is the major cause of sphincter of Oddi dysfunction (SOD), that may be classified as post-cholecystectomy syndrome (PCES). Treatment of PCES requires in most of the cases application of selective antispasmodic drugs.Aim. To evaluate efficacy and safety of hymecromone in patients with post-cholecystectomy SOD, to compare standard and reduced doses of hymecromone.Methods. Overall, 26 patients were enrolled in non-interventional comparative study: 2 males, 24 females, aged from 25 to 74 years. All patients underwent cholecystectomy for symptomatic gallstone disease within 1 to 10 years prior to beginning of the study. All patients were diagnosed to have SOD according to Rome IV Diagnostic Criteria for functional biliary sphincter of Oddi disorder (E1b). All patients underwent hymecromone monotherapy for 3 weeks. Patients were randomized to group A and B to receive full-dose or half-dose of the drug respectively.Results. Abdominal pain completely subsided in 85 % of patients, significant improvement was found for bloating and diarrhea. Mild increase in fasting common bile duct (CBD) diameter after treatment (7.23 ± 0.99 vs 6.78 ± 1.01; p = 0.029) was attributed to choleretic action of hymecromone. Hymecromone resulted in significant improvement of CBD response to fatty meal stimulation (ΔCBD): –1.08 ± 0.46 mm vs –0.10 ± 0.33 mm pretreatment (p = 0.016). Degree of improvement was more pronounced in the group A (full-dose) as compared to group B (half-dose) for abdominal pain (Z = 2.74, p = 0.031), bloating (Z = 2.63, p = 0.035) and constipation (Z = 2.61, p = 0.038)Conclusion. Hymecromone demonstrated itself to be an effective and safe drug, that may be applied both in standard and half dose. However, the efficacy of full-dose is higher both for the treatment of biliary pain and dyspeptic symptoms. Transabdominal ultrasound may be applied as a reliable test for both prediction of treatment efficacy and to monitor patients state during treatment course.

scholarly journals Modern paradigm of functional diseases of gastrointestinal tract: focus on functional dyspepsia, sphincter of Oddi dysfunction and irritable bowel syndrome

2019 ◽  
Vol 3 (20) ◽  
pp. 24-29
Author(s):  
Yu. P. Uspensky ◽  
A. A. Gnutov ◽  
Yu. A. Fominykh ◽  
O. S. Mirzoev
Keyword(s):  
Irritable Bowel Syndrome ◽  
Gastrointestinal Tract ◽  
Functional Dyspepsia ◽  
Functional Gastrointestinal Disorders ◽  
Sphincter Of Oddi ◽  
Gastrointestinal Disorders ◽  
Sphincter Of Oddi Dysfunction ◽  
Oddi Dysfunction ◽  
Irritable Bowel ◽  
Rome Iv

The article presents data on changes in the perception of functional gastrointestinal disorders introduced by the Rome IV criteria. Particular attention is paid to the functional dyspepsia, gallbladder and sphincter of Oddi disorders, the Rome IV criteria.

Calprotectin (S100 A8/A9) and TNF-alpha in differential diagnosis of chronic abdominal pain in children

2017 ◽  
Vol 53 (1) ◽  
pp. 5-10
Author(s):  
Stanisław Pieczarkowski ◽  
Kinga Kowalska-Duplaga ◽  
Andrzej Wędrychowicz ◽  
Krzysztof Fyderek ◽  
Przemko Kwinta ◽  
...  
Keyword(s):  
Differential Diagnosis ◽  
Abdominal Pain ◽  
Functional Gastrointestinal Disorders ◽  
Fecal Calprotectin ◽  
Chronic Abdominal Pain ◽  
Tnf Alpha ◽  
Gastrointestinal Disorders ◽  
Control Group ◽  
Healthy Children ◽  
Inflammatory Bowel

<i>Introduction:</i> Chronic abdominal pain in children is a very frequent and sometimes challenging diagnostic issue. Differential diagnosis in that cases is difficult and often connected with numerous, time-consuming, expensive, and frequently stressful diagnostic studies. The aim of the study was to establish whether fecal calprotectin concentration (FCC) and TNF-alpha may be useful in children with chronic abdominal pain to differentiate between inflammatory bowel disease (IBD), other inflammatory gastrointestinal disorders, and functional gastrointestinal disorders. Methods. The study included patients (median age 13 years), who were assigned to functional gastrointestinal disorders group (n=33); inflammatory gastrointestinal disorders other than IBD (n=71), children with IBD (n=37) and 22 healthy children served as a control group. The concertation of FCC and TNF-alpha in stool samples was measured using ELISA. <i>Results:</i> In healthy children and in children with functional disorders FCCs were below 100 μg/g. In patients with IBD FCCs and TNF-alpha were markedly elevated as compare to children with functional gastrointestinal disorders, however using ROC discrimination of IBD patients was significantly better using FCC than TNF-alpha. <i>Conclusion:</i> FCC is better test for differentiation between IBD, other inflammatory gastrointestinal disorders, and functional gastrointestinal disorders as compare to TNF-alpha concentration in stool. FCC as screening test in patients with chronic abdominal pain should allow to diminish unnecessary diagnostic in cases of functional gastrointestinal disorders.

scholarly journals Sphincter of Oddi Dysfunction: A Perplexing Presentation

2016 ◽  
Vol 10 (3) ◽  
pp. 714-719 ◽  
Author(s):  
Sana Ahmad Din ◽  
Iman Naimi ◽  
Mirza Beg
Keyword(s):  
Abdominal Pain ◽  
Magnetic Resonance Cholangiopancreatography ◽  
Sphincter Of Oddi ◽  
Abdominal Ultrasound ◽  
Sphincter Of Oddi Dysfunction ◽  
Sphincter Pressure ◽  
Abdominal Symptoms ◽  
Biliary Sphincterotomy ◽  
Bile Drainage ◽  
Oddi Dysfunction

Sphincter of Oddi dysfunction is caused by stenosis or dyskinesia of the sphincter of Oddi, leading to blockage of bile drainage from the common bile duct. We present the case of a 16-year-old female with chronic abdominal pain who underwent laparoscopic cholecystectomy for cholelithiasis but continued to experience abdominal pain, nausea, and vomiting along with persistently elevated ALT and AST levels. Postoperative abdominal ultrasound was nondiagnostic. Esophagogastroduodenoscopy showed mild reflux esophagitis and mild chronic Helicobacter pylori-negative gastritis. Omeprazole was started, but it did not decrease the frequency and severity of the abdominal symptoms. Magnetic resonance cholangiopancreatography did not reveal any pathology. Endoscopic retrograde cholangiopancreatography with manometry confirmed an elevated biliary sphincter pressure. Biliary sphincterotomy was performed, and the symptoms improved.

Sign in / Sign up

Export Citation Format

Share Document